Loading stock data...
Last Updated: 10 Mar 2026, 12:50:46 PM (IST)

Mercury Laboratories Limited

BSE: MERCURYLAB

BSE
772.00 -3.05 (-0.39%)

Prev Close

775.05

Open Price

775.05

Volume

37

Today Low / High

772 / 775.05

52 WK Low / High

770 / 976

Range

733 - 811

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 772, reflecting a change of -3.05 (-0.39352%). The expected target range on the BSE is 733 - 811. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

Mercury Laboratories Limited Graph

Mercury Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Mercury Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 772.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 772.00 779.72 701.75 - 857.69
787.44 629.95 - 944.93
795.16 556.61 - 1,033.71
Bearish Scenario 772.00 764.28 687.85 - 840.71
756.56 605.25 - 907.87
748.84 524.19 - 973.49

Overview of Mercury Laboratories Limited

ISIN

INE947G01011

Industry

Medical - Pharmaceuticals

Vol.Avg

113

Market Cap

948,000,000

Last Dividend

3.5

Official Website

Visit Website

IPO Date

2015-02-25

DCF Diff

448.09

DCF

342

Financial Ratios Every Investor Needs

Stock Dividend of MERCURYLAB

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-08-06 August 06, 25 3.5 3.5 2025-08-06 2025-09-11
2024-09-20 September 20, 24 3.5 3.5 2024-09-20 2024-10-26
2023-09-20 September 20, 23 3.5 3.5 2023-09-20 2023-10-27
2022-09-19 September 19, 22 3.5 3.5 2022-09-20 2022-10-27
2021-09-20 September 20, 21 2 2 2021-09-21 2021-10-28

Stock Rating Details for MERCURYLAB

Metric Value Recommendation
Overall Rating C- Strong Sell
DCF Score 3 Neutral
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 2 Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 75.10 Cr 28.92 Cr 46.19 Cr 0.6150 0.00 Cr 1.29 Cr 29.34 Cr 3.14 Cr 26.21 8.09 Cr 0.0419
2024-03-31 75.56 Cr 30.54 Cr 45.02 Cr 0.5958 0.02 Cr 1.60 Cr 7.66 Cr 5.65 Cr 47.12 10.12 Cr 0.0748
2023-03-31 75.33 Cr 30.42 Cr 44.92 Cr 0.5962 0.01 Cr 1.13 Cr 6.26 Cr 5.58 Cr 46.49 10.29 Cr 0.0741
2022-03-31 57.92 Cr 23.66 Cr 34.26 Cr 0.5915 0.02 Cr 0.89 Cr 4.86 Cr 3.56 Cr 29.68 7.93 Cr 0.0615
2021-03-31 68.60 Cr 45.75 Cr 22.85 Cr 0.3331 0.18 Cr 1.12 Cr 8.30 Cr 5.34 Cr 44.48 10.47 Cr 0.0778

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.33 Cr 74.24 Cr 20.67 Cr 53.5692 Cr 5.45 Cr 3.26 Cr 7.21 Cr 33.93 Cr 0.00 Cr 0.00 Cr 0.01 Cr 15.0760 Cr
2024-03-31 3.43 Cr 67.96 Cr 17.12 Cr 50.8385 Cr 5.55 Cr 2.13 Cr 6.21 Cr 27.82 Cr 0.00 Cr 0.00 Cr 0.01 Cr 12.9438 Cr
2023-03-31 3.71 Cr 67.58 Cr 21.95 Cr 45.6289 Cr 5.83 Cr 2.13 Cr 6.90 Cr 24.35 Cr 0.40 Cr 0.04 Cr 0.01 Cr 16.4282 Cr
2022-03-31 4.11 Cr 63.22 Cr 22.88 Cr 40.3408 Cr 5.99 Cr 1.87 Cr 6.78 Cr 25.76 Cr 1.18 Cr 0.00 Cr 0.01 Cr 15.7472 Cr
2021-03-31 3.03 Cr 65.37 Cr 28.48 Cr 36.8946 Cr 7.10 Cr 4.07 Cr 5.16 Cr 26.27 Cr 0.48 Cr 0.00 Cr 0.01 Cr 18.8337 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 4.0011 Cr -9.0399 Cr -0.9945 Cr -5.0388 Cr -6.0333 Cr 2.1932 Cr -9.0399 Cr 3.1449 Cr -0.1030 Cr -0.4200 Cr -1.0002 Cr
2024-03-31 8.2251 Cr -6.2717 Cr -0.6853 Cr 1.9533 Cr 0.9114 Cr 8.2265 Cr -6.2717 Cr 5.6542 Cr 0.1315 Cr -0.4200 Cr 0.6952 Cr
2023-03-31 2.4524 Cr -1.0568 Cr -1.0128 Cr 1.3956 Cr 0.3828 Cr 7.3151 Cr -1.0568 Cr 7.4446 Cr 0.2228 Cr -0.4200 Cr -0.1223 Cr
2022-03-31 5.1889 Cr -1.8920 Cr -1.2307 Cr 3.2744 Cr 2.0662 Cr 6.9323 Cr -1.9145 Cr 5.0311 Cr -1.2110 Cr -0.2400 Cr -1.6211 Cr
2021-03-31 8.2138 Cr -4.6193 Cr -1.2352 Cr 3.5945 Cr 2.3593 Cr 4.8661 Cr -4.6193 Cr 7.9090 Cr -0.0862 Cr -0.4200 Cr 0.3493 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-12-31 18.35 Cr 7.04 Cr 11.31 Cr 0.6164 1.65 Cr 1.00 Cr 8.31 2.44 Cr 0.0544
2025-09-30 19.01 Cr 12.70 Cr 6.31 Cr 0.3319 1.26 Cr 1.64 Cr 13.69 2.92 Cr 0.0865
2025-06-30 18.14 Cr 7.25 Cr 10.89 Cr 0.6002 1.51 Cr 0.97 Cr 8.06 2.54 Cr 0.0534
2025-03-31 20.84 Cr 8.05 Cr 12.79 Cr 0.6137 8.43 Cr 1.11 Cr 9.25 2.30 Cr 0.0533
2024-12-31 19.57 Cr 7.56 Cr 12.01 Cr 0.6138 1.24 Cr 1.19 Cr 9.94 2.51 Cr 0.0609

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 2.83 Cr 0.00 Cr 2.83 Cr 25.02 Cr 7.16 Cr 41.05 Cr 32.89 Cr 74.03 Cr 18.28 Cr
2025-06-30 0.00 Cr 0.00 Cr 1.56 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -53.57 Cr
2025-03-31 2.19 Cr 0.00 Cr 2.19 Cr 25.74 Cr 7.21 Cr 40.08 Cr 33.93 Cr 74.24 Cr 20.67 Cr
2024-12-31 0.00 Cr 0.00 Cr 2.67 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -51.70 Cr
2024-09-30 0.89 Cr 2.03 Cr 2.92 Cr 22.78 Cr 6.13 Cr 36.73 Cr 32.40 Cr 69.43 Cr 17.73 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 0.97 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 1.11 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 1.19 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 0.50 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 0.34 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹830.35 ₹99,644,807,413.00 ₹76,499.00

Key Executives

Chief Financial Officer
Ashish G. Vasavada

Gender: male

Year Born: 1972

Vice President of Marketing & Sales
Mukesh Kumar Shrivastava

Gender: male

Year Born: 1958

Non Executive Non Independent Director & MD of Purchase
Paresh Jagdishbhai Mistry

Gender: male

Year Born: 1969

Chief Executive Officer, MD & Director
Rajendra Ramanlal Shah

Gender: male

Year Born: 1952

Plant Head of Liquid & Tablet
Sandip Patel

Gender: male

Year Born:

Chief Operating Officer
Saurabh Mittal

Gender: male

Year Born: 1985

Company Secretary & Compliance Officer
Krishna Shah

Gender: female

Year Born:

Head of the Department (Dept.-Injectable Production)
Seema Salvi

Gender: female

Year Born: 1976

Quality Assurance Head
Shilpi Bhatnagar

Gender: female

Year Born:

FAQs about Mercury Laboratories Limited

Who is the CEO of the company?

The CEO is Rajendra Ramanlal Shah.

What is the current market price of the stock?

The current price is ₹790.00.

What is the 52-week price range?

The range is ₹736-976.

What is the market capitalization of the company?

The market capitalization is ₹94.80 crores.

What is the dividend yield?

The dividend yield is 0.44%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 20.10.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Mercury Laboratories Limited (ISIN: INE947G01011) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹94.80 crores and an average daily volume of 113 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹3.5.